Chenglangsuo Biotech
层浪生物
Chenglangsuo Biotech
Other
Cenglang Biotech has completed a C+ round of financing worth tens of millions of RMB, which will be invested in high-end flow cytometry R&D and global expansion, consolidating its leading position in China's domestic flow cytometry sector.
Latest round: Series C Extension (2026)
Source: ChinaBulls — chinabulls.com
Last updated 2026-07-31
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.